The U.S. Food and Drug Administration (FDA) approved Qelbree (trilaciclib) for adult use in December 2021. [1] This approval was for the indication of reducing chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer (ES-SCLC) who are receiving myelosuppressive chemotherapy. [1]
How Qelbree Works to Protect Bone Marrow
Qelbree is a first-in-class therapy that acts as a myeloprotection agent. [1] It is designed to protect hematopoietic stem and progenitor cells (HSPCs) from damage caused by chemotherapy. [1] By doing so, Qelbree helps to prevent or reduce the severity of myelosuppression, a common and serious side effect of chemotherapy that leads to a decrease in white blood cells, red blood cells, and platelets. [1]
What Side Effects Have Been Reported?
Common side effects associated with Qelbree include decreased white blood cell count (neutropenia), diarrhea, nausea, vomiting, fatigue, and headache. [1] Serious side effects can include severe neutropenia, febrile neutropenia, and hypersensitivity reactions. [1]
When Does Qelbree's Exclusivity Expire?
Information regarding Qelbree's patent exclusivity is available through resources like DrugPatentWatch.com. [2] DrugPatentWatch.com tracks patent expiry dates for a wide range of pharmaceuticals, providing insights into when generic or biosimilar competition might emerge. [2]
What Other Uses Are Being Explored for Qelbree?
Qelbree is primarily approved for myeloprotection in ES-SCLC patients receiving chemotherapy. [1] Research may explore its efficacy in other cancer types or chemotherapy regimens where myelosuppression is a significant concern. [1]
How Does Qelbree Compare to Other Myeloprotective Agents?
Qelbree is distinguished as a first-in-class myeloprotection agent that directly targets HSPCs. [1] Other myeloprotective strategies often involve growth factors like G-CSF (granulocyte colony-stimulating factor), which stimulate the production of white blood cells. [1] The mechanism of action for Qelbree, protecting stem cells from damage, differs from post-chemotherapy stimulation methods. [1]
What Are the Risks of Qelbree Treatment?
The risks associated with Qelbree include potential for severe neutropenia and febrile neutropenia, which can lead to life-threatening infections. [1] Hypersensitivity reactions are also a concern. [1] Patients are monitored closely for these adverse events during treatment. [1]
What Clinical Data Supported Qelbree's Approval?
Qelbree's FDA approval was based on clinical trials that demonstrated its ability to significantly reduce the incidence of severe neutropenia, neutropenic complications, and the need for transfusions in patients with ES-SCLC undergoing chemotherapy. [1] The specific clinical trial data and its statistical significance are detailed in the drug's prescribing information. [1]
---
Sources:
[1] https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-qelbree-trilaciclib-reduce-chemotherapy-induced-bone-marrow-suppression
[2] https://drugpatentwatch.com/